Treatment of unresectable hepatocellular carcinoma with radiolabelled lipiodol

ANZ Journal of Surgery

Volumn 78, Issue 5, 2008, Pages 371-376

  Kanhere, Harsh A ^a   Leopardi, Lisa N ^a   Fischer, Louise ^a   Kitchener, Michael I ^b   Maddern, Guy J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Hepatocellular carcinoma; Lipiodol; Palliative treatment

Indexed keywords

ALPHA FETOPROTEIN; IODINATED POPPYSEED OIL; STEROID;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HEPATITIS; HUMAN; ISOTOPE LABELING; LIVER CELL CARCINOMA; LUNG SHUNTING; MALE; PHYSICAL EXAMINATION; RADIATION PNEUMONIA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATIC ARTERY; HUMANS; INJECTIONS, INTRA-ARTERIAL; IODINE RADIOISOTOPES; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS;

EID: 41549161686     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2008.04480.x     Document Type: Article

References (16)

1. Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia. Surgeon 2005 3 : 210 15.
2. Yeung YP, Lo CM, Liu CL et al. Natural history of untreated nonsurgical hepatocellular carcinoma. Am. J. Gastroenterol. 2005 100 : 1995 2004.
3. Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann. Surg. 1991 241 : 114 17.
4. Lawson A, Hagan S, Rye K et al. The natural history of hepatitis C with severe hepatic fibrosis. J. Hepatol. 2007 47 : 37 45.
5. Rindani RB, Hugh TJ, Roche J, Roach PJ, Smith RC. 131I-lipiodol therapy for unresectable hepatocellular carcinoma. ANZ J. Surg. 2002 72 : 210 14.
6. Borbath I, Lhommel R, Bittich L et al. 131I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 2005 17 : 905 10.
7. Raoul JL, Guyader D, Bretagne JF et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997 26 : 1156 61.
8. Raoul JL, Guyader D, Bretagne JF et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J. Nucl. Med. 1994 35 : 1782 7.
9. Bretagne JF, Raoul JL, Bourguet P et al. Hepatic arterial injection of I-131-labeled lipiodol: Part II: preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases. Radiology 1988 168 : 547 50.
10. Leung WT, Lau WY, Ho S et al. Selective internal radiation therapy with intra-arterial iodine -131-Lipiodol in inoperable heptocellular carcinoma. J. Nucl. Med. 1994 35 : 1313 18.
11. Yoo HS, Park CH, Lee JT et al. Small hepatocellular carcinoma: high dose internal radiation therapy with superselective intra-arterial injection of I-131-labeled lipiodol. Cancer Chemother. Pharmacol. 1994 33 : S128 33.
12. Keng GH, Sundram FX, Yu SW et al. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using intra-arterial radio-conjugates. Ann. Acad. Med. Singapore 2002 31 : 382 6.
13. Liu CL, Fan ST. Nonresectional therapies for hepatocellular carcinoma. Am. J. Surg. 1997 173 : 358 65.
14. Becker G, Soezgen T, Olschewski M et al. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J. Gastroenterol. 2005 11 : 6104 9.
15. Raoul JL, Boucher E, Olivie D et al. Association of cisplatin and intra-arterial injection of 131I-lipiodol in treatment of hepatocellular carcinoma: results of phase II trial. Int. J. Radiat. Oncol. Biol. Phys. 2006 64 : 745 50.
16. Brans B, Bacher K, Vandevyver V et al. Intra-arterial radionuclide therapy for liver tumours: effect of selectivity of catheterization and 131I-Lipiodol delivery on tumour uptake and response. Nucl. Med. Commun. 2003 24 : 391 6.